Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Compounding Pharmacies topic
No spam. Unsubscribe anytime.
Committee advances bill to let specialty compounding pharmacies sell to retail pharmacies, adds labeling rulemaking
Summary
House Bill 1801 passed committee as amended to align Arkansas law with recent U.S. Food and Drug Administration guidance allowing specialty compounding pharmacies to sell certain products to retail pharmacies; the amendment directs the Board of Pharmacy to promulgate labeling rules.
The Public Health Committee voted to pass House Bill 1801 as amended, aligning Arkansas with recent U.S. Food and Drug Administration (FDA) guidance that permits specialty compounding pharmacies to sell certain compounded products to retail pharmacies for dispensing to patients with valid prescriptions.
State Representative Kendra Moore, sponsor of the bill in committee, said that specialty compounders are licensed and regulated under federal standards when they meet that classification and that the FDA's guidance last year permits these facilities to sell to pharmacies when products are not commercially available. "This bill just brings Arkansas with in line with these FDA guidelines," Moore told the committee, adding that the change applies only when a product is not commercially available and is on the FDA shortage list.
An amendment adopted in committee adds a requirement that the Board of Pharmacy promulgate rules for labeling the contents of compounded products. The sponsor told members that the National Community Pharmacy Association and the state Board of Pharmacy provided input incorporated into the bill.
No witnesses registered for or against the bill during the hearing. The sponsor closed, asking for a do‑pass recommendation. The chair announced the vote with "Ayes have it," and the transcript records that House Bill 1801 passed as amended.
